hat
Genyen vedotin (faz II) 26 ak PSMA-ADC (faz I) 27. Dènyèman, US FDA a apwouve yon ADC MMAE ki gen ADC, brentuximab vedotin (Adcetris®), pou tretman CD30-pozitif Hodgkin lenfom ak sistemik anaplastik gwo-selil lenfom.
eng
Glembatumumab vedotin (phase II)26 and PSMA-ADC (phase I)27. Lately, the US FDA has approved a vc- MMAE-containing ADC, brentuximab vedotin (Adcetris®), for the treatment of CD30-positive Hodgkin lymphoma and systemic anaplastic large-cell lymphoma.